Cost Effectiveness of Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for the First-Line Treatment of Mantle Cell Lymphoma not Eligible for Stem Cell Transplantation- a Scottish Perspective
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1147
https://www.valueinhealthjournal.com/article/S1098-3015(15)03223-4/fulltext
Title :
Cost Effectiveness of Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for the First-Line Treatment of Mantle Cell Lymphoma not Eligible for Stem Cell Transplantation- a Scottish Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03223-4&doi=10.1016/j.jval.2015.09.1147
First page :
A453
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
648